A Phase 4 interventional study of Cyclosporine ophthalmic solution in Dry Eye, sponsored by Research Insight LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by Research Insight LLC · Phase 4, Interventional, and Treatment
Cequa's Onset of Action Trial: an Investigation of CEQUA's Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients
The purpose of this study is to examine the speed of onset of CEQUA ™ in improving the ocular surface among patients with dry eye.
1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.
This study's enrollment of 52 is below the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Research Insight LLC is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
*Patients with the following signs: Central or inferior corneal fluorescein staining defined by the Oxford Scale Reduced tear break up time (TBUT) ≤ 10 seconds.
Exclusion Criteria:
Patient with dry eye disease
Drug: Cyclosporine ophthalmic solution
Cyclosporine BID in the study eye
Also known as: Cequa
Change in corneal high order aberrations (HOA)
Change in corneal HOA
Time frame: After 7, 14, and 28 days of treatment
Change in corneal staining
Corneal staining
Time frame: After 7, 14, 28 days of treatment
Change in best corrected visual acuity
Best corrected visual acuity
Time frame: After 7, 14, and 28 days of treatment
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Research Insight LLC